drugset / Trial / NCT03545971
A Study of IBI310 for the Treatment of Patients With Advanced Solid Tumors.
Non-randomizedSequentialOpen-labelTreatment
Summary
This is an open-label, dose escalation, Phase I study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity and efficacy of single agent of IBI310, and in combination of sintilimab, in patients with advanced solid tumors(Ia) and advanced melanoma(Ib).
Timeline
- Start
- 2018-09-25
- Primary completion
- 2021-09-10
- Completion
- 2022-08-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IBI310 | Monoclonal antibody | 0.3 mg/kg | Intravenous |
| Subject | IBI310 | Monoclonal antibody | 1 mg/kg | Intravenous |
| Subject | IBI310 | Monoclonal antibody | 2 mg/kg | Intravenous |
| Subject | IBI310 | Monoclonal antibody | 3 mg/kg | Intravenous |
| Subject | Sintilimab | Monoclonal antibody | 200 mg | Intravenous |